You had a number of Democratic supporters in there who were applauding at several points. And so this announcement yesterday kind of ties into part of that.Īnd they did have a big announcement. That was something that the administration kept talking to. One part of it, though, that we did hear get a lot of applause - Biden has been talking about it Vice President Harris has been talking about it - is capping the cost of insulin. We weren't all looking at the Medicare aspect of this specifically. But when that act was signed, you know, it was kind of advertised as a climate bill, a big climate bill, a big jobs bill. When we heard Inflation Reduction Act, it meant a lot of things. There was a lot of fanfare, perhaps more fanfare than this policy got when it was originally passed as part of that big, amorphous law known as the Inflation Reduction Act. KEITH: Deepa, you were at the White House yesterday. LUPKIN: That covers medications at the pharmacy counter. KEITH: And to be clear, Medicare Part D is the part of Medicare that covers medications. And if you figure the program spends, you know, north of $200 billion, that's still a huge, huge chunk of how much Medicare Part D is spending on just 10 drugs out of the thousands that it covers. And they make up a big chunk of Medicare Part D spending - somewhere in the neighborhood of $50 billion. So they're like blood thinners like Eliquis and Xarelto. And these are drugs that, not surprisingly, a lot of older Americans who are on Medicare take. LUPKIN: Sure, so the Biden administration announced the first 10 drugs that Medicare will finally be able to actually negotiate their prices. KEITH: So Sydney, tell us about the announcement. We're going to keep standing up to Big Pharma, and we're not going to back down. PRESIDENT JOE BIDEN: We're going to see this through. And on that front, President Biden made a big announcement yesterday. KEITH: So in the current polarized political landscape, there are not a lot of policy ideas that are almost universally popular, but allowing the federal government to negotiate prescription drug prices is one of them. KEITH: And NPR's pharmaceuticals correspondent Sydney Lupkin is here. KEITH: So I feel a kindred spirit with her. You know, I will say last night, for the first time in maybe 20 years, I picked up my bass guitar, and I practiced for, like, an hour. I feel like every music kid, every band kid can relate to that. SHIVARAM: I was going to say, I wonder what she's learning with. KEITH: I would like to hear her ukulele playing. (SOUNDBITE OF THE BIG TOP ORCHESTRA'S "TEETER BOARD: FOLIES BERGERE (MARCH AND TWO-STEP)") LOUISE: Best wishes to you all, and here's the show. LOUISE: Things may have changed by the time you hear this, but I'll still be strumming doggedly away across the pond. LOUISE: It's excruciating but strangely joyful. I'm probably the least musical person in Britain, but now I'm retired, I'm trying to learn the ukulele. The combined strength of Kite and Gilead allows us to remain innovative, agile, and ambitious in our mission to keep improving the lives of people with all types of cancer.LOUISE: Hi, this is Louise (ph) in Manchester, England. As a vital part of Gilead - a founding member of the Foundation for the NIH’s Partnership for Accelerating Cancer Therapies - we are devoted to advancing the understanding of cell therapy as a transformational treatment option for cancer. Since our acquisition by biopharma leader Gilead Sciences in October 2017, our combined strength has accelerated the advancement of our pipeline, including the launch of YESCARTA® (axicabtagene ciloleucel) and TECARTUS® (brexucabtagene autoleucel), and has expanded the impact of our strategic partnerships.Īs an independent operating company since 2019, we prioritize innovative R&D with the full resources, capabilities, and trust of Gilead. OUR STORY A SINGULAR FOCUS ON CELL THERAPYįounded in 2009 as a pioneer in cell therapy research, Kite’s leadership position in the immuno-oncology space was solidified with our research and development agreement with the National Cancer Institute in 2012 and when our commercial manufacturing site opened in El Segundo in 2016. Our industry-leading cell therapy technology uses the power of a patient's own immune system (their white blood cells) to target and attack their cancer cells. We believe cell therapy has the ability to change the way cancer is treated. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit. OUR MISSION TRANSFORMATIONAL CANCER TREATMENTĪt Kite, our singular focus is cell therapy to treat and potentially cure cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |